Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention
-
Published:2024-04
Issue:
Volume:391
Page:117472
-
ISSN:0021-9150
-
Container-title:Atherosclerosis
-
language:en
-
Short-container-title:Atherosclerosis
Author:
Ray Kausik K.ORCID,
Gunn Laura H.,
Conde Lorena Garcia,
Raal Frederick J.,
Wright R. Scott,
Gosselin Nathalie H.,
Leiter Lawrence A.,
Koenig Wolfgang,
Schwartz Gregory G.,
Landmesser Ulf
Reference34 articles.
1. World Heart Federation cholesterol Roadmap 2022;Ray;Glob Heart,2022
2. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur. Heart J.,2017
3. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel;Boren;Eur. Heart J.,2020
4. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study;Roth;J. Am. Coll. Cardiol.,2020
5. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur. Heart J.,2019
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献